Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per Arthritis Care & Research,almost 20-50% of people suffering from ankylosing spondylitis are reported to show spinal progression of certain level in the last two years of follow-up.
The TNF inhibitor treatments and NSAIDs (Non-steroid anti-inflammatory drugs) have been cornerstone therapies regarding managing ankylosing spondylitis and other types of inflammatory arthritis conditions.
The European Congress of Rheumatology (EULAR) annual meeting presented a French study raising a concern that rheumatologists, in spite of being knowledgeable about biosimilars, abstain from switching over to them due to lack of confidence in this treatment option.
On the other hand, European Journal of Integrative Medicine, Sep 2019, stated that Moxibustion, a type of heat therapy combined with traditional treatments is likely to provide short-term benefit to the ones affected by ankylosing spondylitis. This therapy is already put into practice all over East Asia.
Besides, findings at the Universita Degli Studi del Molise (Italy) state that physiotherapy is advantageous for ankylosing spondylitis-affected patients.
Though anti-inteleukin medications and anti-tumor necrosis have improved prognosis for a sizable number of patients; physiotherapy helps those who do not respond positively to these drugs. Moreover, modern day treatments press for physical rehabilitation and therapy.
Of late, research conducted at the University of Medical Sciences (Iran) concluded that T reg cells (suppressing the immune system) were upregulated in ankylosing spondylitis-affected patients who received a dose of nanocurcumin for 4 months in a row. Turmeric contains curcumin in the form of a naturally-occurring yellow colored substance.
The factors mentioned above are expected to compel the governments to divert a greater portion of their revenue towards extensive research, thereby driving the ankylosing spondylitis treatment market.
The ankylosing spondylitis treatment market players are focusing on innovation and approval to gain a competitive edge over one another.
This trend is bound to help the ankylosing spondylitis market stand in a better stead between 2020 and 2030.
For instance –
Principal Consultant
Ankylosing Spondylitis infected patients need to be extra careful amidst Covid-19. If they, by any means, signal towards active respiratory infection, they should consult their medical practitioner before continuing with the medications as that infection could be Covid-19, which may ask for a combination of varied medications/precautions.
The healthcare industry is moving towards extensive research with regards to ankylosing spondylitis, so as to continue with the geometric progression on the count of innovations.
For instance –
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The ankylosing spondylitis treatment market players have been devising biosimilars to combat ankylosing spondylitis.
Also, branded drugs’ patent expiry is opening doors for biosimilars. For instance – Remicade expired in 2015. This resulted in Inflectra getting introduced in 2016. The year 2017 witnessed introduction of Renflexis. Likewise, in 2019, Avsola got introduced.
The major players in the ankylosing spondylitis treatment market include:
The ankylosing spondylitis treatment market, as stated by FMI, is expected to witness a steady growth rate between 2020 and 2030.
The market players are working on war footing to devise medications for ankylosing spondylitis.
Inorganic growth parameters could also be pondered about. For instance – strategic partnerships across various geographies could help in reaching out to more number of patients
Drug Class
Route of Administration
Application
Region
The ankylosing spondylitis treatment market is likely to secure a CAGR of 4.6% through 2032.
The ankylosing spondylitis treatment market size is estimated to cross US$ 5.1409 Bn by 2032.
The ankylosing spondylitis treatment market is likely to record a value of US$ 8.06 Bn in 2022.
North America is likely to lead the ankylosing spondylitis treatment market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Product Adoption / Usage Analysis 4.2. Product USPs / Features 4.3. Key Promotional Strategies 5. Global Market - Pricing Analysis 5.1. Regional Pricing Analysis By Drug Class 5.2. Pricing Break-up 5.2.1. Manufacturer Level Pricing 5.2.2. Distributor Level Pricing 5.3. Global Average Pricing Analysis Benchmark 6. Global Market Demand (in Value or Value in US$ Mn) Analysis 2015-2019and Forecast, 2020-2030 6.1. Historical Market Value (US$ Mn) Analysis, 2015-2019 6.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Market Background 7.1. Macro-Economic Factors 7.1.1. Global GDP Growth Outlook 7.1.2. Increase In Spending per Capita Income 7.2. Forecast Factors - Relevance & Impact 7.2.1. Product Availability 7.2.2. Rising Number of Ankylosing Spondylitis Cases 7.2.3. Development of Products 7.2.4. Change in Lifestyle Pattern 7.3. Value Chain Analysis 7.4. Market Dynamics 7.4.1. Drivers 7.4.2. Restraints 7.4.3. Opportunity Analysis 7.5. COVID19 Crisis Analysis 7.5.1. Current COVID19 Statistics and Probable Future Impact 7.5.2. Current GDP Projection and Probable Impact 7.5.3. Current Economic Projection as compared to 2008 Economic analysis 7.5.4. COVID19 and Impact Analysis 7.5.4.1. Revenue By Drug Class 7.5.4.2. Revenue By Route of Administration 7.5.4.3. Revenue By Application 7.5.4.4. Revenue By Country 7.5.5. 2020 Market Scenario 7.5.6. Quarter by Quarter Forecast 7.5.7. Projected recovery Quarter 7.5.8. Recovery Scenario – Short term, Midterm and Long Term Impact 8. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class 8.1. Introduction / Key Findings 8.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2015 - 2019 8.3. Current and Future Market Value (US$ Mn) Value Analysis and Forecast By Drug Class, 2020 - 2030 8.3.1. Disease-Modifying Anitrheumatic Drugs (DMARDs) 8.3.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 8.3.3. Biologics 8.4. Market Attractiveness Analysis By Drug Class 9. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Value (US$ Mn) Analysis By Route of Administration , 2015 - 2019 9.3. Current and Future Market Value (US$ Mn) Value Analysis and Forecast By Route of Administration , 2020 - 2030 9.3.1. Oral 9.3.2. Parenteral 9.4. Market Attractiveness Analysis By Route of Administration 10. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Application 10.1. Introduction / Key Findings 10.2. Historical Market Value (US$ Mn) Value Analysis By Application, 2015 - 2019 10.3. Current and Future Market Value (US$ Mn) Value Analysis and Forecast By Application , 2020 - 2030 10.3.1. Juveniles 10.3.2. Adults 10.4. Market Attractiveness Analysis By Application 11. Global Market Analysis 2015-2019 and Forecast 2020-2030, by Region 11.1. Introduction 11.2. Historical Market Value (US$ Mn) Analysis By Region, 2015 - 2019 11.3. Current Market Value (US$ Mn) Analysis and Forecast By Region, 2020 - 2030 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. Middle East and Africa (MEA) 11.3.5. East Asia 11.3.6. South Asia 11.3.7. Oceania 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2015-2019 and Forecast 2020-2030 12.1. Introduction 12.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019 12.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Application 12.4. Market Attractiveness Analysis 12.4.1. By Drug Class 12.4.2. By Route of Administration 12.4.3. By Application 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 13. Latin America Market Analysis 2015-2019 and Forecast 2020-2030 13.1. Introduction 13.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019 13.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Rest of Latin America 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Application 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Route of Administration 13.4.4. By Application 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 14. Europe Market Analysis 2015-2019 and Forecast 2020-2030 14.1. Introduction 14.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019 14.3. Market Value (US$ Mn) By Market Taxonomy, 2020 - 2030 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Application 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Route of Administration 14.4.4. By Application 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 15. South Asia Market Analysis 2015-2019 and Forecast 2020-2030 15.1. Introduction 15.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019 15.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Application 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Route of Administration 15.4.4. By Application 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 16. East Asia Market Analysis 2015-2019 and Forecast 2020-2030 16.1. Introduction 16.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019 16.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Drug Class 16.3.3. By Route of Administration 16.3.4. By Application 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Route of Administration 16.4.4. By Application 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 17. Oceania Market Analysis 2015-2019 and Forecast 2020-2030 17.1. Introduction 17.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019 17.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Application 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Route of Administration 17.4.4. By Application 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 18. Middle East and Africa Market Analysis 2015-2019 and Forecast 2020-2030 18.1. Introduction 18.2. Historical Market Value (US$ Mn) Analysis By Market Taxonomy, 2015 - 2019 18.3. Market Value (US$ Mn) Forecast By Market Taxonomy, 2020 - 2030 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. Northern Africa 18.3.1.4. South Africa 18.3.1.5. Rest of Middle East and Africa 18.3.2. By Drug Class 18.3.3. By Route of Administration 18.3.4. By Application 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Route of Administration 18.4.4. By Application 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 19. Key and Emerging Countries Market Analysis 2015-2019 and Forecast 2020-2030 19.1. Introduction 19.1.1. Market Value Proportion Analysis, By Key Countries 19.1.2. Global Vs. Country Growth Comparison 19.2. U.S. Market Analysis 19.2.1. By Drug Class 19.2.2. By Route of Administration 19.2.3. By Application 19.3. Canada Market Analysis 19.3.1. By Drug Class 19.3.2. By Route of Administration 19.3.3. By Application 19.4. Mexico Market Analysis 19.4.1. By Drug Class 19.4.2. By Route of Administration 19.4.3. By Application 19.5. Brazil Market Analysis 19.5.1. By Drug Class 19.5.2. By Route of Administration 19.5.3. By Application 19.6. U.K. Market Analysis 19.6.1. By Drug Class 19.6.2. By Route of Administration 19.6.3. By Application 19.7. Germany Market Analysis 19.7.1. By Drug Class 19.7.2. By Route of Administration 19.7.3. By Application 19.8. France Market Analysis 19.8.1. By Drug Class 19.8.2. By Route of Administration 19.8.3. By Application 19.9. Italy Market Analysis 19.9.1. By Drug Class 19.9.2. By Route of Administration 19.9.3. By Application 19.10. Spain Market Analysis 19.10.1. By Drug Class 19.10.2. By Route of Administration 19.10.3. By Application 19.11. Russia Market Analysis 19.11.1. By Drug Class 19.11.2. By Route of Administration 19.11.3. By Application 19.12. China Market Analysis 19.12.1. By Drug Class 19.12.2. By Route of Administration 19.12.3. By Application 19.13. Japan Market Analysis 19.13.1. By Drug Class 19.13.2. By Route of Administration 19.13.3. By Application 19.14. South Korea Market Analysis 19.14.1. By Drug Class 19.14.2. By Route of Administration 19.14.3. By Application 19.15. India Market Analysis 19.15.1. By Drug Class 19.15.2. By Route of Administration 19.15.3. By Application 19.16. Australia Market Analysis 19.16.1. By Drug Class 19.16.2. By Route of Administration 19.16.3. By Application 19.17. New Zealand Market Analysis 19.17.1. By Drug Class 19.17.2. By Route of Administration 19.17.3. By Application 19.18. GCC Countries Market Analysis 19.18.1. By Drug Class 19.18.2. By Route of Administration 19.18.3. By Application 19.19. Turkey Market Analysis 19.19.1. By Drug Class 19.19.2. By Route of Administration 19.19.3. By Application 19.20. South Africa Market Analysis 19.20.1. By Drug Class 19.20.2. By Route of Administration 19.20.3. By Application 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Concentration 20.3. Market Share Analysis of Top Players 20.4. Market Presence Analysis 20.4.1. By Regional footprint of Players 20.4.2. Product foot print by Players 20.4.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. AbbVie, Inc. 21.3.1.1. Overview 21.3.1.2. Product Portfolio 21.3.1.3. Profitability by Market Segments (Product/Channel/Region) 21.3.1.4. Sales Footprint 21.3.1.5. Strategy Overview 21.3.1.5.1. Marketing Strategy 21.3.1.5.2. Product Strategy 21.3.1.5.3. Channel Strategy 21.3.2. Amgen, Inc. 21.3.2.1. Overview 21.3.2.2. Product Portfolio 21.3.2.3. Profitability by Market Segments (Product/Channel/Region) 21.3.2.4. Sales Footprint 21.3.2.5. Strategy Overview 21.3.2.5.1. Marketing Strategy 21.3.2.5.2. Product Strategy 21.3.2.5.3. Channel Strategy 21.3.3. Pfizer, Inc. 21.3.3.1. Overview 21.3.3.2. Product Portfolio 21.3.3.3. Profitability by Market Segments (Product/Channel/Region) 21.3.3.4. Sales Footprint 21.3.3.5. Strategy Overview 21.3.3.5.1. Marketing Strategy 21.3.3.5.2. Product Strategy 21.3.3.5.3. Channel Strategy 21.3.4. Novartis AG 21.3.4.1. Overview 21.3.4.2. Product Portfolio 21.3.4.3. Profitability by Market Segments (Product/Channel/Region) 21.3.4.4. Sales Footprint 21.3.4.5. Strategy Overview 21.3.4.5.1. Marketing Strategy 21.3.4.5.2. Product Strategy 21.3.4.5.3. Channel Strategy 21.3.5. Eli Lilly and Company 21.3.5.1. Overview 21.3.5.2. Product Portfolio 21.3.5.3. Profitability by Market Segments (Product/Channel/Region) 21.3.5.4. Sales Footprint 21.3.5.5. Strategy Overview 21.3.5.5.1. Marketing Strategy 21.3.5.5.2. Product Strategy 21.3.5.5.3. Channel Strategy 21.3.6. UCB, Inc. 21.3.6.1. Overview 21.3.6.2. Product Portfolio 21.3.6.3. Profitability by Market Segments (Product/Channel/Region) 21.3.6.4. Sales Footprint 21.3.6.5. Strategy Overview 21.3.6.5.1. Marketing Strategy 21.3.6.5.2. Product Strategy 21.3.6.5.3. Channel Strategy 21.3.7. Johnson & Johnson Services, Inc. 21.3.7.1. Overview 21.3.7.2. Product Portfolio 21.3.7.3. Profitability by Market Segments (Product/Channel/Region) 21.3.7.4. Sales Footprint 21.3.7.5. Strategy Overview 21.3.7.5.1. Marketing Strategy 21.3.7.5.2. Product Strategy 21.3.7.5.3. Channel Strategy 21.3.8. Merck & Co., Inc. 21.3.8.1. Overview 21.3.8.2. Product Portfolio 21.3.8.3. Profitability by Market Segments (Product/Channel/Region) 21.3.8.4. Sales Footprint 21.3.8.5. Strategy Overview 21.3.8.5.1. Marketing Strategy 21.3.8.5.2. Product Strategy 21.3.8.5.3. Channel Strategy 21.3.9. Janssen Pharmaceuticals Inc 21.3.9.1. Overview 21.3.9.2. Product Portfolio 21.3.9.3. Profitability by Market Segments (Product/Channel/Region) 21.3.9.4. Sales Footprint 21.3.9.5. Strategy Overview 21.3.9.5.1. Marketing Strategy 21.3.9.5.2. Product Strategy 21.3.9.5.3. Channel Strategy 21.3.10. Sandoz International GmbH 21.3.10.1. Overview 21.3.10.2. Product Portfolio 21.3.10.3. Profitability by Market Segments (Product/Channel/Region) 21.3.10.4. Sales Footprint 21.3.10.5. Strategy Overview 21.3.10.5.1. Marketing Strategy 21.3.10.5.2. Product Strategy 21.3.10.5.3. Channel Strategy 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Ankylosing Spondylitis Treatment Market
